FSD Pharma (Nasdaq: HUGE) Enters into License Agreement to Develop FDA approved Veterinary Drugs

Summary: FSD Pharma Inc. (Nasdaq: HUGE) ...announces that it has entered into a license agreement with Innovet Italia S.R.L, under which Innovet granted the Company a license to use ultramicronized PEA to develop FDA approved veterinary drugs for the treatment of gastro-intestinal diseases in Dogs and Cats. In addition, the Company today announces the filing of its year-end results and provides corporate updates. “The licensing agreement with Innovet Italia S.R.I, to evaluate the use of ultra- micro PEA as a veterinary anti-inflammatory prescription drug, is an exciting opportunity for the company to enter into a new and untapped market,” said Dr. Raza Bokhari, Executive Chairman & CEO. “With a balance sheet that is stronger today than it was when we began our journey nearly three years ago, we are actively exploring other M&A and licensing opportunities to expand our drug development pipeline.” Innovet Italia is an innovative animal health company, founded in Italy in 1996. Its main goal is to bring scientific innovation in niche fields of the veterinary market. About FSD Pharma FSD Pharma Inc. is a publicly-traded holding company trading on the Nasdaq with Stock Symbol HUGE. FSD BioSciences, Inc., a wholly-owned subsidiary, is a specialty biotech pharmaceutical R&D company. https://www.fsdpharma.com Read Full Press Release: https://greenstocknews.com/news/nasdaq/huge/fsd-pharma-enters-into-license-agreement-to-develop-fda-approved-veterinary-drugs-for-the-treatment-of-gastro-intestinal-diseases-in-dogs-and-cats Green Stock News for the New Green Economy. For more information visit: https://www.greenstocknews.com​​